AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
AstraZeneca Pharma India Limited - Asset Resilience Ratio
AstraZeneca Pharma India Limited (ASTRAZEN) has an Asset Resilience Ratio of 25.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how AstraZeneca Pharma India Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down AstraZeneca Pharma India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹4.00 Billion | 24.77% |
| Short-term Investments | ₹105.60 Million | 0.65% |
| Total Liquid Assets | ₹4.11 Billion | 25.42% |
Asset Resilience Insights
- Very High Liquidity: AstraZeneca Pharma India Limited maintains exceptional liquid asset reserves at 25.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
AstraZeneca Pharma India Limited Industry Peers by Asset Resilience Ratio
Compare AstraZeneca Pharma India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for AstraZeneca Pharma India Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for AstraZeneca Pharma India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 34.63% | ₹5.26 Billion | ₹15.18 Billion | -10.75pp |
| 2024-03-31 | 45.38% | ₹4.89 Billion | ₹10.78 Billion | -6.26pp |
| 2023-03-31 | 51.64% | ₹5.09 Billion | ₹9.85 Billion | -1.12pp |
| 2022-03-31 | 52.76% | ₹4.52 Billion | ₹8.57 Billion | +6.94pp |
| 2021-03-31 | 45.82% | ₹3.55 Billion | ₹7.75 Billion | +10.32pp |
| 2020-03-31 | 35.51% | ₹2.51 Billion | ₹7.06 Billion | +4.55pp |
| 2019-03-31 | 30.96% | ₹1.74 Billion | ₹5.62 Billion | +4.66pp |
| 2018-03-31 | 26.30% | ₹1.21 Billion | ₹4.61 Billion | -1.10pp |
| 2017-03-31 | 27.40% | ₹1.14 Billion | ₹4.15 Billion | +27.40pp |
| 2016-03-31 | 0.00% | ₹94.54K | ₹4.49 Billion | -5.46pp |
| 2015-03-31 | 5.47% | ₹225.00 Million | ₹4.12 Billion | -14.51pp |
| 2014-03-31 | 19.97% | ₹830.00 Million | ₹4.16 Billion | +14.58pp |
| 2013-03-31 | 5.39% | ₹165.02 Million | ₹3.06 Billion | -9.23pp |
| 2012-03-31 | 14.62% | ₹500.07 Million | ₹3.42 Billion | +8.28pp |
| 2007-03-31 | 6.34% | ₹152.12 Million | ₹2.40 Billion | -3.07pp |
| 2006-03-31 | 9.41% | ₹165.16 Million | ₹1.75 Billion | -30.52pp |
| 2005-03-31 | 39.94% | ₹668.68 Million | ₹1.67 Billion | -- |